Completed PHASE1 INTERVENTIONAL NCT00423839

A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers

Sponsor: University of Oxford

Interventions MVA85A (Tuberculosis vaccine)

Updated 5 times since 2017 Last updated: Jan 17, 2007 Started: Mar 31, 2003 Completion: Jul 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00423839, this PHASE1 trial focuses on Tuberculosis and remains completed. Sponsored by University of Oxford, it has been updated 5 times since 2003, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2017 — Jan 2021 [monthly]

Completed PHASE1

First recorded

Mar 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Oxford

Data source: University of Oxford

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Fajara, The Gambia